104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain.

dc.contributor.authorPereyra-Rodriguez, Jose Juan
dc.contributor.authorDominguez-Cruz, Javier
dc.contributor.authorArmario-Hita, Jose Carlos
dc.contributor.authorRuiz-Villaverde, Ricardo
dc.date.accessioned2025-01-07T13:25:39Z
dc.date.available2025-01-07T13:25:39Z
dc.date.issued2021-09-27
dc.identifier.doi10.1016/j.abd.2020.08.030
dc.identifier.essn1806-4841
dc.identifier.pmcPMC8790214
dc.identifier.pmid34593266
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8790214/pdf
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.abd.2020.08.030
dc.identifier.urihttps://hdl.handle.net/10668/25495
dc.issue.number6
dc.journal.titleAnais brasileiros de dermatologia
dc.journal.titleabbreviationAn Bras Dermatol
dc.language.isoen
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
dc.page.number787-790
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshAntibodies, Monoclonal, Humanized
dc.subject.meshDermatitis, Atopic
dc.subject.meshDermatology
dc.subject.meshDouble-Blind Method
dc.subject.meshHumans
dc.subject.meshSeverity of Illness Index
dc.subject.meshSpain
dc.subject.meshTreatment Outcome
dc.title104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number96

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC8790214.pdf
Size:
743.44 KB
Format:
Adobe Portable Document Format